Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.
Lilly stock popped on Tuesday after the company announced that its oral GLP-1 pill helped patients lose an average of 10.5% of their body weight and reduced blood sugar levels, meeting key goals in the pivotal Phase 3 trial.
